Drug Trial Radar · NCT03847909
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Oct 28, 2019
Primary completion
Jun 21, 2021
Study completion Jun 29, 2021
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Primary Hyperoxaluria Type 2 (PH2)
- Kidney Diseases
- Urologic Diseases
- Genetic Disease
Interventions
DCR-PHXCDrug
Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
Sterile Normal Saline (0.9% NaCl)Drug
Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC From Day 90 To Day 180, Based on Percent Change From Baseline in 24-Hour UoxTime frame: From Day 90 to 180
Locations
28 sites in 15 countries. Site status is shown where the registry gives one.
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
New York, New York
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Herston, Australia
Clinical Trial Site
Parkville, Australia
Clinical Trial Site
Hamilton, Canada
Clinical Trial Site
Bron, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Heidelberg, Germany
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Roma, Italy
Clinical Trial Site
Nagoya, Japan
Clinical Trial Site
Tochigi, Japan
Clinical Trial Site
Tokyo, Japan
Clinical Trial Site
Beirut, Lebanon
Clinical Trial Site
Beirut, Lebanon
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Auckland, New Zealand
Clinical Trial Site
Bialystok, Poland
Clinical Trial Site
Bucharest, Romania
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Santa Cruz, Spain
Clinical Trial Site
Birmingham, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.